Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer’s-related psychosis during the ...

Bristol Myers Squibb (BMY) ended the recent trading session at $56.29, demonstrating a -0.16% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

Valued at a market cap of $113.1 billion, Bristol-Myers Squibb Company (BMY) is a leading global biopharmaceutical company ...

Financial giants have made a conspicuous bullish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb BMY revealed 10 unusual trades. Delving into the details ...

Arsenal Biosciences, Inc., a clinical-stage programmable cell therapy company, announced Monday that drug maker Bristol-Myers Squibb ...

Every investor in Bristol-Myers Squibb Company (NYSE:BMY) should be aware of the most powerful shareholder groups. With 78% stake, institutions possess the maximum shares in the company.

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a ...

Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars ...